Difference between revisions of "Hepatoblastoma"
Jump to navigation
Jump to search
Line 11: | Line 11: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
=High-risk, upfront therapy= | =High-risk, upfront therapy= | ||
+ | ==COG AHEP0731 protocol W {{#subobject:3a8i39|Regimen=1}}== | ||
+ | <div class="toccolours" style="background-color:#eeeeee"> | ||
+ | ===Protocol {{#subobject:a15cb47|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | !style="width: 33%"|Study | ||
+ | !style="width: 33%"|Years of enrollment | ||
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5665173/ Katzenstein et al. 2017 (COG AHEP0731)] | ||
+ | |9/2009-2/2012 | ||
+ | | style="background-color:#91cf61" |Non-randomized | ||
+ | |- | ||
+ | |} | ||
+ | </div></div> | ||
+ | ===References=== | ||
+ | #'''COG AHEP0731:''' Katzenstein HM, Furman WL, Malogolowkin MH, Krailo MD, McCarville MB, Towbin AJ, Tiao GM, Finegold MJ, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Rodriguez-Galindo C, Meyers RL. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer. 2017 Jun 15;123(12):2360-2367. Epub 2017 Feb 17. [https://doi.org/10.1002/cncr.30591 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc5665173/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/28211941/ PubMed] NCT00980460 | ||
+ | |||
==SIOPEL-4 protocol {{#subobject:3a6ad9|Regimen=1}}== | ==SIOPEL-4 protocol {{#subobject:3a6ad9|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#eeeeee"> | <div class="toccolours" style="background-color:#eeeeee"> |
Revision as of 01:50, 28 February 2023
7 regimens on this page
7 variants on this page
|
High-risk, upfront therapy
COG AHEP0731 protocol W
Protocol
Study | Years of enrollment | Evidence |
---|---|---|
Katzenstein et al. 2017 (COG AHEP0731) | 9/2009-2/2012 | Non-randomized |
References
- COG AHEP0731: Katzenstein HM, Furman WL, Malogolowkin MH, Krailo MD, McCarville MB, Towbin AJ, Tiao GM, Finegold MJ, Ranganathan S, Dunn SP, Langham MR, McGahren ED, Rodriguez-Galindo C, Meyers RL. Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee. Cancer. 2017 Jun 15;123(12):2360-2367. Epub 2017 Feb 17. link to original article link to PMC article PubMed NCT00980460
SIOPEL-4 protocol
Protocol
Study | Years of enrollment | Evidence |
---|---|---|
Zsiros et al. 2013 (SIOPEL-4) | 1/1/2005-8/31/2009 | Non-randomized |
References
- SIOPEL-4: Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G; International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol. 2013 Aug;14(9):834-42. Epub 2013 Jul 4. link to original article link to PMC article PubMed NCT00077389
Adjuvant therapy
Cisplatin & Fluorouracil (CF) & Vincristine
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Katzenstein et al. 2019 (AHEP0731) | 2010-2014 | Phase 3 (E-esc) | Observation | Seems to have superior EFS |
For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.
Preceding treatment
- Curative surgical resection
Chemotherapy
- Cisplatin (Platinol) by the following weight-based criteria:
- Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
- 10 kg or more: 100 mg/m2 over 6 hours once on day 1
- Fluorouracil by the following weight-based criteria:
- Less than 10 kg: 20 mg/kg IV once on day 2
- 10 kg or more: 600 mg/m2 IV once on day 2
- Vincristine by the following weight-based criteria:
- Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
- 10 kg or more: 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 2, 9, 16
21-day cycle for 1 cycle (to be given within 42 days of resection)
References
- AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article link to PMC article PubMed NCT00980460
All lines of therapy
Cisplatin monotherapy
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Perilongo et al. 2009 (SIOPEL 3) | 1998-2006 | Phase 3 (E-de-esc) | Cisplatin & Doxorubicin | Non-inferior complete resection rate | |
Brock et al. 2018 (SIOPEL 6) | 2007-2014 | Phase 3 (C) | Cisplatin & Sodium thiosulfate | More hearing loss |
Chemotherapy
References
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
- SIOPEL 6: Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. link to original article link to PMC article PubMed NCT00652132
Cisplatin & Doxorubicin
PLADO: PLAtinol (Cisplatin) & DOxorubicin
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy | Comparative Toxicity |
---|---|---|---|---|---|
Ortega et al. 2000 | 1989-1992 | Phase 3 (E-switch-ic) | CF & Vincristine | More toxic | |
Pritchard et al. 2000 (SIOPEL 1) | 1990-1994 | Non-randomized | |||
Perilongo et al. 2009 (SIOPEL 3) | 1998-2006 | Phase 3 (C) | Cisplatin | Non-inferior complete resection rate |
Chemotherapy
References
- Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
- SIOPEL 1: Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. link to original article PubMed
- SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912